The research data platform Flywheel has announced that Roche (OTCMKTS:RHHBY) and its subsidiary Genentech are using its cloud-scale informatics platform to ingest, standardize and analyze medical imaging data to streamline drug discovery.
Minneapolis-based Flywheel says the process provides a swifter and more efficient means to curate data at the terabyte and petabyte scales. Specifically, Roche and Genentech are using the platform to assist in finding answers to core scientific questions related to patient care and outcomes.
“With our platform in place, Roche and Genentech researchers can access high-quality images for complex analysis and machine learning, ultimately speeding the development of innovative therapies,” said Jim Olson, CEO of Flywheel, in a press release. “Before using the platform, this level of collaboration and analysis was simply not possible.”
Image courtesy of Flywheel
A number of prominent research institutions, including Stanford University, Columbia University, Mount Sinai, Massachusetts General Hospital and St. Jude Children’s Hospital, also use Flywheel technology.
In September, the company announced a $22 million Series C funding round led by 8VC.
Flywheel received a final Series C investment earlier this month of $5.5 million, bringing its total Series C round to $27.5 million.
Intuitive Ventures, the venture capital division of robotic surgery pioneer Intuitive (NSDQ:ISRG), led the most recent fundraising round.
Flywheel has expanded its offerings by acquiring Radiologics, enabling it to provide a broader number of features for data management for clinical trials and greater functionality related to DICOM metadata. St. Louis, Missouri–based Radiologics had developed a suite of services related to imaging informatics.
Filed Under: Drug Discovery
